Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1523-1530

  Jiao, Feng ^a   Hu, Hai ^a   Yuan, Cuncun ^a   Jin, Ziliang ^a   Guo, Zhen ^a   Wang, Liwei ^a   Wang, Lei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell invasion; Drug resistance; Histone deacetylases 3; Histone modification; Pancreatic cancer

Indexed keywords

HISTONE DEACETYLASE 3; PROTEIN BAX; PROTEIN P27; PROTEIN P53; BAX PROTEIN, HUMAN; DEOXYCYTIDINE; GEMCITABINE; HISTONE; HISTONE DEACETYLASE; PROTEASOME; PSMD9 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DEACETYLATION; EPIGENETICS; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PANCREATIC DUCTAL EPITHELIAL CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE; TUMOR INVASION;

BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907465107     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2568     Document Type: Article

References (32)

1. Ducreux M, Boige V, Goere D, Deutsch E, Ezra P, Elias D and Malka D: The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. Best Pract Res Clin Gastroenterol 21: 997-1014, 2007.
2. Ghaneh P, Costello E and Neoptolemos JP: Biology and management of pancreatic cancer. Postgrad Med J 84: 478-497, 2008.
3. Chueh A C, Togel L, Mariadason J and Tse JW: Mechanisms of HDAC inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal March 27, 2014 [Epub ahead of print].
4. West AC and Johnstone RW: New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124: 30-39, 2014.
5. Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol 6: 579-589, 2012.
6. Huang X, Ji G, Wu Y, Wan B and Yu L: LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis. J Cancer Res Clin Oncol 134: 705-714, 2008.
7. Xue Y, Ren H, Xiao W, Chu Z, Lee JJ and Mao L: Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. Int J Oncol 41: 1798-1808, 2012.
8. Giovannetti E, Del TM, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del CM, Iannopollo M, Bevilacqua G, Mosca F and Danesi R: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928-3935, 2006.
9. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L and Depinho RA: Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103: 5947-5952, 2006.
10. Ansari D, Rosendahl A, Elebro J and Andersson R: Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 98: 1041-1055, 2011.
11. Hamada S, Masamune A, Miura S, Satoh K and Shimosegawa T: MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal 26: 179-185, 2014.
12. Chen Z, Chen L Y, Dai H Y, Wang P, Gao S and Wang K: miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem 113: 3229-3235, 2012.
13. Genin P, Lin R, Hiscott J and Civas A: Recruitment of histone deacetylase 3 to the interferon-A gene promoters attenuates interferon expression. PLoS One 7: e38336, 2012.
14. Karagianni P and Wong J: HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 26: 5439-5449, 2007. (Pubitemid 47255926)
15. Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herbolsheimer E, Zeitlinger J, Lewitter F, Gifford DK and Young RA: Genomewide map of nucleosome acetylation and methylation in yeast. Cell 122: 517-527, 2005. (Pubitemid 41191151)
16. Guenther M G, Levine SS, Boyer LA, Jaenisch R and Young RA: A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130: 77-88, 2007. (Pubitemid 47031323)
17. Liu C, Liu L, Shan J, Shen J, Xu Y, Zhang Q, Yang Z, Wu L, Xia F, Bie P, Cui Y, Zhang X, Bian X and Qian C: Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. Cancer Lett 339: 60-69, 2013.
18. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Motoyama S and Ogawa J: Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol 31: 533-539, 2010.
19. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche F R, Niesporek S, Denkert C, Dietel M and Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610, 2008. (Pubitemid 351214528)
20. Wu LM, Yang Z, Zhou L, Zhang F, Xie H Y, Feng XW, Wu J and Zheng SS: Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 5: e14460, 2010.
21. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH and Davidsen SK: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536, 2003. (Pubitemid 37163696)
22. Zhu J, Wan H, Xue C, Jiang T, Qian C and Zhang Y: Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration. Brain Res 1520: 15-22, 2013.
23. Campos B, Bermejo J L, Han L, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A and Herold-Mende C: Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102: 387-392, 2011.
24. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47: 137-147, 2008. (Pubitemid 351231442)
25. Sonnemann J, Marx C, Becker S, Wittig S, Palani CD, Kramer OH and Beck J F: p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer 110: 656-667, 2014.
26. Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE, Rao VN, Bhat GK and Reddy ES: Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 39: 111-119, 2011.
27. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY and Nam SW: HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 113: 2167-2177, 2012.
28. Nimmanapalli R, Fuino L, Stobaugh C, Richon V and Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236-3239, 2003. (Pubitemid 36858020)
29. Huang L and Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866, 2000.
30. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET and Yu Q: Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102: 16090-16095, 2005. (Pubitemid 41552872)
31. Xu W, Ngo L, Perez G, Dokmanovic M and Marks PA: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103: 15540-15545, 2006. (Pubitemid 44625628)
32. Reichert N, Choukrallah MA and Matthias P: Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 69: 2173-2187, 2012.